Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer
DOI:
https://doi.org/10.3889/oamjms.2018.022Keywords:
cetuximab, epidermal growth factor receptor, non-melanoma skin cancer, targeted treatment, skin toxicitiesAbstract
BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common malignancy in humans. Targeted therapy with monoclonal antibody cetuximab is an option in case of advanced tumor or metastasis.
AIM: We present and update of the use of cetuximab in NMSC searching PUBMED 2011-2017.
METHODS: The monoclonal antibody cetuximab against epidermal growth factor receptor (EGFR) has been investigated for its use in NMSC during the years 2011 to 2017 by a PUBMED research using the following items: “Non-melanoma skin cancer AND cetuximab,†“cutaneous squamous cell carcinoma AND cetuximab,†and “basal cell carcinoma AND cetuximabâ€, and “cetuximab AND skin toxicityâ€. Available data were analyzed including case reports.
RESULTS: Current evidence of cetuximab efficacy in NMSC was mainly obtained in cutaneous SCC and to a lesser extend in BCC. Response rates vary for neoadjuvant, adjuvant, mono- and combined therapy with cetuximab. Management of cutaneous toxicities is necessary. Guidelines are available.
CONCLUSIONS: Cetuximab is an option for recurrent or advanced NMSC of the skin. It seems to be justified particularly in very high-risk tumors. There is a need for phase III trials.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin cancer: Epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther (Heidelb). 2017; 7(Suppl 1):5-19. https://doi.org/10.1007/s13555-016-0165-y PMid:28150105 PMCid:PMC5289116
Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013; 20:248-54. https://doi.org/10.1177/107327481302000402 PMid:24077401 PMCid:PMC4516026
Piselli P, Verdirosi D, Cimaglia C, Busnach G, Fratino L, Ettorre GM, De Paoli P, Citterio F, Serraino D. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. Best Pract Res Clin Obstet Gynaecol. 2014; 28:1251-65. https://doi.org/10.1016/j.bpobgyn.2014.08.007 PMid:25209964
Muehleisen B, Pazhenkottil A, French LE, Hofbauer GF. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration. JAMA Dermatol. 2013; 149:618-20. https://doi.org/10.1001/jamadermatol.2013.3115 PMid:23677099
Wollina U. Addiction to Tanning – A new cause of early onset of nonmelanoma skin cancer. Open Dermatol J. 2009; 3:86-8. https://doi.org/10.2174/1874372200903010086
Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013; 12:568-72. PMid:23652953
Newlands C, Currie R, Memon A, Whitaker S, Woolford T. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130:S125-S132. https://doi.org/10.1017/S0022215116000554 PMid:27841126 PMCid:PMC4873942
Wollina U, Tchernev G. Advanced basal cell carcinoma. Wien Med Wochenschr. 2013; 163:347-53. https://doi.org/10.1007/s10354-013-0193-5 PMid:23589318
Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. 2017; 10:1645-1653. https://doi.org/10.2147/OTT.S130910 PMid:28352196 PMCid:PMC5360396
Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2013; 29:87-92. https://doi.org/10.1097/IOP.0b013e3182831bf3 PMid:23446297 PMCid:PMC3878052
Amaral T, Garbe C. Non-melanoma skin cancer: new and future synthetic drug treatments. Expert Opin Pharmacother. 2017; 18:689-699. https://doi.org/10.1080/14656566.2017.1316372 PMid:28414587
Wollina U. Cetuximab for non-melanoma skin cancer. Expert Expert Opin Biol Ther. 2012; 12:949-56. https://doi.org/10.1517/14712598.2012.681374 PMid:22519406
Muzic JG, Schmitt AR, Wright AC, Alniemi DT, Zubair AS, Olazagasti Lourido JM, Sosa Seda IM, Weaver AL, Baum CL. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: A population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017; 92:890-898. https://doi.org/10.1016/j.mayocp.2017.02.015 PMid:28522111
Barton V, Armeson K, Hampras S, Ferris LK, Visvanathan K, Rollison D, Alberg AJ. Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. Arch Dermatol Res. 2017; 309:243-51. https://doi.org/10.1007/s00403-017-1724-5 PMid:28285366
Kricker A, Weber M, Sitas F, Banks E, Rahman B, Goumas C, Kabir A, Hodgkinson VS, van Kemenade CH, Waterboer T, Armstrong BK. Early life UV and risk of basal and squamous cell carcinoma in New South Wales, Australia. Photochem Photobiol. 2017. [Epub ahead of print]. https://doi.org/10.1111/php.12807
Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012; 106:811-5. https://doi.org/10.1002/jso.23155 PMid:22592943
O'Bryan K, Sherman W, Niedt GW, Taback B, Manolidis S, Wang A, Ratner D. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2013; 69:595-602. https://doi.org/10.1016/j.jaad.2013.05.011 PMid:23871719
Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011; 29:3419-26. https://doi.org/10.1200/JCO.2010.34.1735 PMid:21810686
Kim S, Eleff M, Nicolaou N. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. Head Neck. 2011; 33:286-8. https://doi.org/10.1002/hed.21299 PMid:19953623
Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric modulated arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep. 2011; 3:e57. https://doi.org/10.4081/dr.2011.e57 PMid:25386308 PMCid:PMC4211506
Giacchero D, Barriere J, Benezery K, Guillot B, Dutriaux C, Mortier L, Lacour JP, Thyss A, Peyrade F. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma - a report of eight cases. Clin Oncol (R Coll Radiol). 2011; 23:716-18. https://doi.org/10.1016/j.clon.2011.07.007 PMid:21831617
Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012; 3:257-61. https://doi.org/10.7150/jca.3491 PMid:22712026 PMCid:PMC3376776
Mecca C, Ponzetti A, Clainedo V, Ciuffreda L, Lista P. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol. 2012; 22:758-61. PMid:23131415
Eder J, Simonitsch-Klupp I, Trautinger F. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies – a case series. Eur J Dermatol. 2013; 23:658-62. PMid:24135559
Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014; 113:871-7. https://doi.org/10.1111/bju.12450 PMid:24053151 PMCid:PMC4321685
Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A. Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. Dermatology. 2014; 229(2):97-101. https://doi.org/10.1159/000362384 PMid:24923455
Seber S, Gonultas A, Ozturk O, Yetisyigit T. Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy. Onco Targets Ther. 2016; 9:945-8. https://doi.org/10.2147/OTT.S96227 PMid:26955287 PMCid:PMC4772919
Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol. 2017; 114:102-13. https://doi.org/10.1016/j.critrevonc.2017.03.032 PMid:28477738
Wehler TC, Graf C, Möhler M, Herzog J, Berger MR, Gockel I, Lang H, Theobald M, Galle PR, Schimanski CC. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol. 2013; 139:1667-72. https://doi.org/10.1007/s00432-013-1483-4 PMid:23918349 PMCid:PMC3771414
Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E. Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian expert recommendations. Am J Clin Oncol. 2016; 39:407-15. https://doi.org/10.1097/COC.0000000000000291 PMid:27077276
Kajizono M, Saito M, Maeda M, Yamaji K, Fujiwara S, Kawasaki Y, Matsunaga H, Sendo T. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Int J Clin Oncol. 2013; 18:684-8. https://doi.org/10.1007/s10147-012-0427-3 PMid:22678464
Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. 2017; 25(7):2179-85. https://doi.org/10.1007/s00520-017-3623-x PMid:28197850
Saintes C, Saint-Jean M, Brocard A, Peuvrel L, Renaut JJ, Khammari A, Quéreux G, Dréno B. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol. 2015; 29:1006-9. https://doi.org/10.1111/jdv.12526 PMid:24980899
Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol. 2014; 171:431-3. https://doi.org/10.1111/bjd.12840 PMid:24446722
Zhu GA, Sundram U, Chang AL. Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol. 2014; 150:970-3. https://doi.org/10.1001/jamadermatol.2014.583 PMid:24740281
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
